Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib Conditioning for Allo-SCT in Multiple Myeloma
NCT00995059Phase 2Withdrawn
- Sponsor
- Mayo Clinic
- Modality
- Small Molecules, Modified Peptides
01
Overview
A Phase 2 trial of bortezomib in multiple myeloma (MM), sponsored by Mayo Clinic. Status: withdrawn.
02
Drugs
bortezomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00995059.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00995059.